Zach Levine supports clients in market access, product commercialization, and reimbursement strategy.

He applies his background in qualitative research and health policy to help clients understand the evolving U.S. health market and optimize product access and delivery.

Prior to joining Avalere, Zach worked at ASRC Federal as a contractor for the Centers for Medicare and Medicaid Services (CMS), where he supported CMS’ Office of Information Technology. Before that, he held positions as a research assistant with the Vaccine Confidence Project, London School of Hygiene and Tropical Medicine, and as a legal intern with the Camden Coalition ACO in New Jersey.

Zach has an AB in anthropology from Princeton University with a Certificate in Global Health and Health Policy.

Authored Content

As treatment advancements in oncology continue, stakeholders are modifying their approaches to defining value and managing care

The kidney care payment and delivery landscape was poised for change in 2020 due to existing policies and market trends. Given the specific risk COVID-19 poses to these patients, the pandemic is creating new challenges and potentially accelerating existing trends in the kidney care space.

Tune in to hear the final episode in our 3-part series that focuses on CMS’s most recent proposed payment rules. In episode 3, we’ll be focusing on the End Stage Renal Disease (ESRD) Prospective Payment System, with a focus on proposed payment changes for innovative drugs, supplies, and equipment and updates to the Quality Incentive Program (QIP).

Recent developments in the specialty pharmaceutical marketplace merit distinct attention from manufacturers.